Abstract

Primary cutaneous diffuse large B-cell lymphoma, leg type, is diagnosed in 20-25 % cases of all primary cutaneous B-cell lymphomas, primarily in elderly women (older than 70 years). The disease has aggressive recurrent progression and worse prognosis than other variants. The standard antitumor drug therapy are such regimens as R-CHOP and CHOP-like programs including anthracycline antibiotics. Use of these programs can be limited by the presence of cardiovascular and other concomitant disorders.Due to the limited variety of combinations of antitumor agents, low frequency of diagnosis of this immunomorphological variant of lymphoproliferative disease and absence of a single algorithm of drug therapy, every clinical case is interesting and informative.In the presented clinical case, an 80-year-old female patient with primary cutaneous diffuse large B-cell lymphoma, leg type, and concomitant pathology of the cardiovascular system underwent 2 courses of R-CVP regimen drug therapy without anthracyclines. A significant antitumor clinical effect was achieved in the form of complete tumor regression. Treatment was not accompanied by significant toxicity which allowed to complete therapy.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call